Tag: (NASDAQ:ONCE)

May 2, 2019

FDA to Ramp Up Efforts in Gene Therapy Development

The number of gene therapy products in development is growing, and the FDA is advancing its efforts to move these...
April 16, 2019

Biotech Market Update: Q1 2019 in Review

With Q1 2019 officially over, the Investing News Network shares a biotech market update on the biggest news and trends...
December 19, 2018

Biotech Outlook 2019: Will the Pressure Continue?

With 2018 coming to an end, what's the biotech outlook? Next year will bring new investing opportunities for those in...
November 23, 2018

European Commission Approves Spark Therapeutics’ LUXTURNA

Spark Therapeutics (NASDAQ:ONCE), a fully integrated, commercial gene therapy company dedicated to challenging the inevitability of genetic disease, today announced...
October 30, 2018

Spark Therapeutics Presents Three Post-hoc Analyses from Phase 3 Clinical Trial of LUXTURNA

Spark Therapeutics (NASDAQ:ONCE), a fully integrated, commercial gene therapy company dedicated to challenging the inevitability of genetic disease, today announced...
October 16, 2018

Pharmaceutical Update: Q3 2018 in Review

With Q3 behind us and Q4 already in full swing, the Investing News Network is providing a look at some...
September 25, 2018

Investing in Stem Cell Treatments

Stem cell treatments have grabbed investor attention for years, but can be complex and potentially dangerous. Here is an overview...